Edarbi is owned by Azurity.
Edarbi contains Azilsartan Kamedoxomil.
Edarbi has a total of 3 drug patents out of which 0 drug patents have expired.
Edarbi was authorised for market use on 25 February, 2011.
Edarbi is available in tablet;oral dosage forms.
Edarbi can be used as treatment of hypertension.
The generics of Edarbi are possible to be released after 26 March, 2028.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 11 months from now) | |
US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(5 years from now) |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic